Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Phase 2

Completed

• Conditions: Seasonal Influenza
• Interventions: Biological: Seasonal Influenza Vaccine (MF59C.1)

• Registration Number: NCT00956761
• Lead Sponsor: Novartis

Brief Summary

This is a trial for annual registration of the updated seasonal influenza vaccine formulation.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Study First Submitted: 2009-08-08
• Study First Submitted QC: 2009-08-10
• Study First Posted: 2009-08-11
• Status Verified: 2015-12
• Results First Submitted: 2015-12-21
• Results First Submitted QC: 2015-12-21
• Last Update Submitted: 2015-12-21
• Results First Posted: 2016-01-27
• Last Update Posted: 2016-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

• Subjects of 65 years of age or older
• Mentally competent
• Willing and able to give written informed consent prior to study entry
• Able to comply with all the study requirements
• In general good health

Key

Exclusion Criteria

• Any serious chronic or acute disease disease
• History of any anaphylactic reaction and/or serious allergic reaction following a vaccination
• A proven hypersensitivity to any component of the study vaccine
• Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age)
• Bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject
• Within the past 12 months, participants had received more than one injection of influenza vaccine
• Within the past 6 months, participants had laboratory confirmed influenza disease or received influenza vaccine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Seasonal Influenza Vaccine (MF59C.1)	-

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD	Day 21	Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 21), evaluated using SRH assay.; Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase.; The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).
Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD	day 21	Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 21).; The CHMP criterion was met if the geometric mean increase (GMR, day 21/day 0) in SRH antibody area is \>2.0 (≥65 years).
Number of Participants Who Reported Solicited Local and Systemic Reactions	0-3 days post-vaccination	Safety was assessed for participants who reported solicited local and systemic reactions from day 0 up to and including day 3 after the FLUAD vaccination.
Percentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD	day 21	Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 0) and three weeks after FLUAD vaccination (day 21).; This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).

Trial Locations

Locations (2)

Site 2: Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37; 🇮🇹 Lanciano, Italy

Site 3: Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48; 🇮🇹 Pianiga, Italy